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Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) 
mutation is thought to be related with dismal outcome for non–small-
cell lung cancer (NSCLC) patients. The role of KRAS mutation as a 
predictor of response to chemotherapy for patients with metastatic 
NSCLC is poorly understood.
Methods: From a retrospective database of two university hospitals, 
all patients with advanced, nonsquamous NSCLC treated with first-line 
platinum-containing chemotherapy were selected. Mutation analysis 
for KRAS was performed and the relation with response to chemother-
apy was assessed. Secondary endpoints were its relation with response 
to progression-free survival (PFS) and overall survival (OS).
Results: A total of 161 patients, 94 men and 67 women, were included 
in this study. Median age was 60 years. The majority of patients 
(79%) had stage IV disease, of which 60 patients (37%) had a KRAS 
mutation. Patients with a KRAS mutation had a similar response to 
treatment as patients with KRAS wild-type (wt) (p = 0.77). Median 
PFS in KRAS-mutated patients was 4.0 months versus 4.5 months 
in KRAS wt patients (hazard ratio = 1.3; [95% confidence interval, 
0.9–1.8]; p = 0.16). Median OS in patients with KRAS mutation 
was 7.0 months versus 9.3 months in patients with KRAS wt (hazard 
ratio = 1.2; [95% confidence interval, 0.9–1.7]; p = 0.25). Type of 
KRAS mutation had no influence on response or outcome.
Conclusion: On the basis of our multicenter data presented here, we 
conclude that KRAS mutation is not predictive for worse response 
to chemotherapy, PFS, and OS in advanced NSCLC patients treated 
with platinum-based chemotherapy in first-line setting.
Key Words: Non–small-cell lung cancer, Kirsten rat sarcoma viral onco-
gene homolog mutation, Predictive biomarker, Prognostic biomarker.
(J Thorac Oncol. 2013;8: 1190-1195)
Kirsten rat sarcoma viral oncogene homolog (KRAS) muta-tion is the most common driver mutation in non–small-cell 
lung cancer (NSCLC) and is present in approximately 30% of 
all NSCLC patients, mainly in patients with adenocarcinoma 
(AC) histology. Other mutations in rat sarcoma viral oncogene 
homolog (RAS) gene family include mutations in Harvey rat sar-
coma viral oncogene homolog (HRAS) and neuroblastoma rat 
sarcoma viral oncogene homolg (NRAS) but these are observed 
in less than 10% of the RAS mutations in NSCLC. RAS pro-
teins circulate signals from growth receptors on the cell surface 
to intracellular effector pathways responsible for cell growth and 
proliferation. Mutations most often occur in codons 12, 13, or 
61 of the RAS gene (located on chromosome 12) and result in 
an irreversible continuous activation of RAS protein.1–3 Because 
of the critical role of RAS protein in cell proliferation, NSCLC 
patients with a KRAS mutation are believed to have a worse 
prognosis as compared with patients with a KRAS wild type 
(wt). The relation between KRAS mutational status and survival 
was first reported in 1990.4 Since then, a variety of studies have 
investigated the influence of KRAS mutational status on survival, 
however, even today, conflicting results are reported.
It is believed that patients with a KRAS mutation do not 
respond to chemotherapy treatment, although at this moment, 
chemotherapy is the only treatment option for these patients.5 In 
contrast, successful targeted agents are developed for patients 
with an EGFR mutation and EML4-ALK translocation.6,7 
Few studies have investigated the effect of KRAS mutation on 
response to first-line chemotherapy in patients with advanced 
NSCLC.8–10 These studies conclude that patients with a KRAS 
mutation do not have worse response to chemotherapy treatment. 
Though, because of the small sample size and differences in 
type of chemotherapy used in these studies, this finding remains 
open to debate. The aim of our retrospective study is to evaluate 
the association of KRAS mutational status with response to 
chemotherapy, progression-free survival (PFS), and overall 
survival (OS) in patients with advanced NSCLC treated with 
platinum-based chemotherapy as first-line treatment.
PATIENTS AND METHODS
Study Patients
We retrospectively selected all consecutive nonsquamous 
(p63-negative) NSCLC patients by searching pathology reports 
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in two university hospitals from 2004 to January 2011. Patients 
were eligible for the study on the basis of the following crite-
ria: proven incurable stage IIIb or IV (tumor, node, metastasis 
[TNM] 6th edition) NSCLC, treatment with first-line platinum-
containing chemotherapy, availability of tumor material for 
KRAS mutation analysis, at least one target lesion according to 
Response Evaluation Criteria in Solid Tumours 1.0, and evalu-
able computed tomography before and after treatment. Palliative 
radiotherapy during chemotherapy treatment was allowed. The 
following data were retrieved from the medical records: age, 
sex, smoking history, World Health Organisation performance 
status (PS), histology (including p63 staining results), stage of 
disease (Union for International Cancer Control [UICC] 6th 
edition), chemotherapy treatment, number of courses, response 
to treatment according to the Response Evaluation Criteria in 
Solid Tumours 1.0, date of start of treatment, date of progres-
sion, and date of death or date of last contact.
Ethics Statement
This study was approved by the ethics committee of the 
VU University Medical Center Amsterdam; according to our 
local rules, informed consent was not needed for this retro-
spective study.
Immunohistochemistry
To distinguish between AC and squamous cell car-
cinoma and thyroid transcription factor 1 (TTF1) and p63, 
immunohistochemistry staining was performed on all 
patients, according to a previously described protocol.11 
For TTF1 clones 8G7G3/1 were used and for p63 clones 
4A4 were used. A single observer scored the stained slides 
for intensity (0 = negative, 1 = weak, 2 = moderate, and 
3 = strongly positive) and percentage of positive tumor cells 
with 10% increments. For each immunohistochemical stain, a 
total score was obtained by multiplying intensity and percent-
age of positive tumor cells. A score more than 240 was con-
sidered positive for p63. This threshold was chosen because it 
clearly delineates squamous cell carcinoma from AC differenti-
ation.12 For TTF1 a positive threshold of more than 30 was used, 
as even minor staining is associated with AC differentiation.
Mutation Analyses
Tumor tissue was manually macrodissected from serial 
sections guided by a hematoxylin-eosin–stained tissue sec-
tion, on which the tumor area was marked by a pathologist. 
DNA was extracted and subjected to high-resolution melting 
and sequencing analysis for KRAS exon 2 and 3, according to 
routine protocol.13,14
Statistical Analysis
The primary objective was to evaluate the difference in 
probability of response between patients with KRAS wt and 
KRAS mutation. Secondary objectives were PFS, defined as 
time from start of treatment till objective disease progression 
or death, and OS defined as the time from start of treatment 
till death. The relationship between KRAS mutational status 
and patient characteristics, type of chemotherapy treatment, or 
response was calculated using Pearson’s χ2 test. Kaplan–Meier 
curve was used to estimate the distribution of survival accord-
ing to KRAS mutational status. Log-rank test was used to cal-
culate difference in survival among the subgroups. To estimate 
the hazard ratio (HR), Cox regression analysis was used. In 
addition, analysis was performed for different types of KRAS 
mutation. For the latter analysis, types of KRAS mutations that 
had a frequency of less than 5 were clustered in one group.
RESULTS
From the retrospective databases, 161 patients were 
eligible for the study. The patient characteristics are listed in 
Table 1. The median age was 60 years (range, 34–83 years), 
17 patients (10.3%) had a PS of more than 1. The majority of 
patients had stage IV disease (79%). A total of 115 patients 
(71.4%) had an AC, 46 patients (29.6%) were diagnosed with 
NSCLC not otherwise specified favoring AC.
Treatment
According to the inclusion criteria, all patients received 
a platinum combination. Eighty-nine patients were treated 
with cisplatin, 69 patients were treated with carboplatin, and 
three patients received both regimens. Platinum was most fre-
quently combined with gemcitabine (51.6%). Other partners 
were pemetrexed (31.1%), docetaxel (16.8%), and vinorelbine 
(0.6%). The median amount of chemotherapy courses was 
four. In total, there was one patient (0.6%) with a complete 
remission, 31 patients (19.3%) had a partial response (PR), 
77 patients (47.8%) had a stable disease (SD), and 52 patients 
(30.7%) had progressive disease (PD).
KRAS Mutation
KRAS mutations were present in 60 patients (37.3%), of 
which the majority of patients had stage IV disease (85.0%). 
There was no significant relationship among patient charac-
teristics as listed in Table 1 and KRAS mutational status. Also, 
there were no differences in treatment among patients with or 
without a KRAS mutation (p = 0.90) or in amount of courses 
administered (p = 0.31). For KRAS wt patients, platinum dou-
blet chemotherapy resulted in 1 complete remission (1.0%), 21 
PRs (20.8%), 48 SDs (47.5%), and 31 PDs (30.7%). Responses 
in the KRAS-mutated group included 10 PRs (16.7%), 29 SDs 
(48.3%), and 21 PDs (35.0%; p = 0.77) (Fig. 1).
The different types of mutation are presented in 
Figure 2. The most frequent mutations observed were: p.G12C 
(41.7%), p.G12V (16.7%), p.G12D (11.7%), and p.G13C 
(10.0%). There were no differences between type of mutation 
and response to therapy (p = 0.98).
PFS and OS
The median follow-up was 48 months. Date of death 
was assessed on October 1, 2011. Median PFS in KRAS-
mutated patients was 4.0 months (95% CI, 2.8–5.2 months) 
versus 4.7 months (95% CI, 3.2–6.1 months) in KRAS wt 
patients (HR = 1.3; [95% CI, 0.9–1.8]; p = 0.12) (Fig. 3A). 
Median OS in patients with KRAS mutation was 7.0 months 
(95% CI, 3.9–10.2) versus 9.3 months (95% CI, 6.6–11.9) 
in patients with KRAS wt (HR = 1.2; [95% CI, 0.9–1.7]; 
p = 0.25) (Fig. 3B). Classic prognostic factors, such as stage 
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(HR = 1.6; [95% CI, 1.0–2.5]), histology (AC versus large cell; 
HR = 1.6; [95% CI, 1.1–2.3]), and PS (HR = 1.5; [95% CI, 1.2–
2.0]) were found to be prognostic factors. The 1-year survival 
was 36.7 and 46.1% in KRAS-mutated and KRAS-wt patients, 
respectively. The PFS and OS were comparable in the different 
types of KRAS mutation (p = 0.90 and p = 0.99, respectively).
DISCUSSION
In this retrospective study of a consecutive cohort 
of patients, we observed no differences in response to first-
line platinum-based chemotherapy treatment in advanced 
NSCLC patients with or without a KRAS mutation. Although 
median OS and the 1-year survival rate was worse in patients 
TABLE 1.  Patient Characteristics
KRAS Wild-Type KRAS Mutation
n % n % Sign (p < 0.05)
Median, age (range, yr) 61 (34–80) 58 (35–83) 0.61
Sex 0.33
 M 56 55.4 38 63.3 —
 F 45 44.6 22 36.7 —
Smoking history 0.09
 Never 12 13.5 2 3.5 —
 Former 41 46.1 25 43.9 —
 Current 36 40.4 30 52.6 —
WHO PS 0.61
 0 43 45.7 23 40.4 —
 1 40 42.6 28 49.1 —
 2 9 9.6 6 10.5 —
 3 2 2.1 0 0.0 —
Histology 0.68
 Adenocarcinoma 71 70.3 44 73.3 —
 NSCLC-NOS 30 29.7 16 26.7 —
Stage 0.18
 IIIb 24 23.8 9 15.0 —
 IV 77 76.2 51 85.0 —
Platinum regimen 0.91
 Carboplatin 2 2.0 1 1.7 —
 Cisplatin 42 41.6 27 45.0 —
 Both 57 56.4 32 53.3 —
Chemotherapy regimen 0.90
 Gemcitabine 52 51.5 31 51.7 —
 Pemetrexed 31 30.7 19 31.7 —
 Docetaxel 17 16.8% 10 16.7 —
 Vinorelbine 1 1.0 0 0.0 —
WHO PS, World Health Organisation performance status; NSCLC-NOS, non–small-cell lung cancer not otherwise specified.
FIGURE 1.  Histogram of response (in %) in patients 
with KRAS wt or KRAS mut. CR, complete remission; 
KRAS, Kirsten rat sarcoma viral oncogene homolog; 
mut, mutation; PD, progressive disease; PR, partial 
response; SD, stable disease; wt, wild type.
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harboring a KRAS mutation, this was not statistically signifi-
cantly different.
The aggressive behavior of KRAS mutation in NSCLC 
patients was first suggested by Slebos et al.4 in 1990, who 
reported worse survival of KRAS-mutated NSCLC patients. 
The hypothesis is provided by the function and downstream 
effectors of the RAS protein family, including the mitogen-
activated protein kinase (MAPK) pathway. An activating 
KRAS mutation could, therefore, result in continuous stimula-
tion of tumor proliferation, resulting in early progression and 
poor survival. In accordance with other studies, we found that 
response and PFS were not significantly worse in advanced 
NSCLC patients with a KRAS mutation. (Table 2). In a prospec-
tive trial, 62 patients with inoperable stage III or IV NSCLC 
were treated with mesna, ifosfamide, carboplatin, and etopo-
side. Sixteen patients (25.8%) had a KRAS mutation. In three of 
16 patients (19%) with a KRAS mutation there was response to 
treatment, compared with a response rate of 26% in KRAS-wt 
patients. This difference in response was not significant 
(p = 0.49). The PFS and OS were not significantly different 
in patients with KRAS wt and KRAS mutation.8 Another study 
evaluated mutational status and response to treatment using 
data of the TRIBUTE trial. This was a randomized phase III 
study in advanced NSCLC, comparing first-line chemother-
apy with first-line chemotherapy with concurrent erlotinib. 
Of 274 patients, 264 had tumor material available for KRAS-
mutation analysis. In 55 patients (21%) a KRAS mutation was 
present. No differences in response were seen between KRAS-
mutated patients treated in the erlotinib-containing arm and 
the chemotherapy-only arm (8% versus 23%, respectively; 
p = 0.16). Also, no differences in PFS and OS was observed 
in patients either with, or without a KRAS mutation.9 Recently, 
a study evaluated clinical outcome in advanced NSCLC 
patients receiving first-line chemotherapy according to EGFR 
and KRAS mutational status. In this study, 162 patients were 
treated with first-line chemotherapy. Thirty of 133 patients 
(22.6%) had a KRAS mutation. No difference in response 
to chemotherapy was found between patients with KRAS 
mutation or KRAS wt (25.0% versus 26.5%, respectively; 
FIGURE 2.  Histogram of type of KRAS mutation. 
KRAS, Kirsten rat sarcoma viral oncogene homolog. 
FIGURE 3. A, PFS in months. Continuous line KRAS wt 
(median PFS 4.7 months), dashed line KRAS mut (median PFS 
4.0 months). HR = 1.3 (95% CI, 0.9–1.8). B, OS in months. 
Continuous line KRAS wt (median OS 9.3 months), dashed 
line KRAS mut (median OS 7.0 months). HR = 1.2 (95% CI, 
0.9–1.7). CI, confidence interval; HR, hazard ratio; KRAS, Kirsten 
rat sarcoma viral oncogene homolog; mut, mutation; os, overall 
survival; PFS, progression-free survival; wt, wild type.
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p = 0.87). In patients treated with platinum-based chemo-
therapy (96 patients, of which 18 patients were with a KRAS 
mutation) there were also no differences in response (29.2% 
versus 30.2%, respectively; p = 0.95). The PFS and OS was 
comparable in patients with or without a KRAS mutation.10
A variety of studies have investigated the prognostic 
role of KRAS mutational status. Unfortunately, these stud-
ies were equivocal because of differences in patient selec-
tion, stage of disease, histology, and type of treatment. In the 
early 1990s, KRAS mutation was reported to be a poor prog-
nostic factor in early-stage NSCLC patients who underwent 
surgery.4,15,16 However, in subgroup analysis of prospective 
studies in NSCLC, KRAS mutational status was not found to 
be prognostic.17,18 In a meta-analysis on the prognostic role 
of KRAS mutational status in NSCLC, reviewing 53 studies 
and 5216 patients, KRAS mutational status was found to be 
a poor prognostic factor. Patients with a KRAS mutation had 
a worse survival with an HR of 1.40 (95% CI, 1.18–1.65).19 
Unfortunately, a multivariate analysis with prognostic factors 
such as PS and stage of disease was not performed.
A post hoc power analysis for response rate and 1-year 
survival rate (SAS 9.2; β = 0.9; α = 0.05; weight is 3 for KRAS-
mutated patients and 5 for KRAS wt) demonstrated that with 
our sample size, a reduction of 20% in 1-year survival could 
be detected with a power of 0.80. Prospective studies should 
be conducted to answer the question whether KRAS mutational 
status has prognostic or predictive value. However, based on 
the studies discussed above and our findings, KRAS mutational 
status does not seem to have a clinically relevant impact on 
PFS and OS. Therefore, the value of KRAS mutational status 
in NSCLC as predictor of poor outcome has to be reviewed.
A very interesting hypothesis is that different types of 
KRAS mutation are associated with different responses to che-
motherapy regimens. Garassino et al.20 described this in a study 
on KRAS-mutated NSCLC cell lines. Differences were found in 
three types of KRAS mutation: p.G12C, p.G12V, and p.G12D. In 
comparison with the WT clones, p.G12C mutation was associ-
ated with a reduced response to cisplatin, but increased sensitiv-
ity to taxol and pemetrexed, whereas p.G12V mutation showed 
a strong sensitivity to cisplatin, less sensitivity to pemetrexed. 
Cell lines harboring a p.G12D mutation showed resistance to 
taxol, but sensitivity to sorafenib. Another recently published 
study reported poor survival in patients with KRAS p.G12C 
and p.G12V, treated with molecular targeted therapy compared 
with other types of KRAS mutation.21 This study used data of 
the Biomarker-integrated Approaches of Targeted Therapy for 
Lung Cancer Elimination (BATTLE) trial, in which a total of 
255 patients were randomized to erlotinib, vandetanib, bexaro-
tene, and erlotinib or sorafenib.22 A total of 43 patients had a 
KRAS mutation; of these, 24 patients had a p.G12C or p.G12V 
mutation. KRAS mutational status was not associated with OS 
or PFS (p = 0.09). When KRAS mutations were clustered in 
p.G12C + p.G12V and others, there was a significant difference 
in median PFS when compared with KRAS wt (1.8, 3.4, and 
2.0 months, respectively; p = 0.046). In our patient population, 
we could not confirm these data, but the sample size was prob-
ably too small to find relevant differences between the types of 
KRAS mutation. We encourage further study on type of KRAS 
mutation and its relation to response to chemotherapy and prog-
nosis in a larger cohort of patients.
CONCLUSION
On the basis of our multicenter data presented here, we 
conclude that KRAS mutational status is not likely to be pre-
dictive for worse response or PFS in advanced nonsquamous 
NSCLC patients treated with platinum-based chemotherapy 
in first-line setting.
REFERENCES
 1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
 2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
2011;144:646–674.
 3. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a 
tumorigenic web. Nat Rev Cancer 2011;11:761–774.
 4. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation 
as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 
1990;323:561–565.
 5. Adjei AA. K-ras as a target for lung cancer therapy. J Thorac Oncol 
2008;3(6 Suppl 2):S160–S163.
 6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhi-
bition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–1703.
 7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epider-
mal growth factor receptor underlying responsiveness of non-small-cell 
lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
 8. Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras 
oncogene and the effect of chemotherapy in advanced adenocarcinoma of 
the lung: a prospective study. J Clin Oncol 1997;15:285–291.
 9. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epider-
mal growth factor receptor and in KRAS are predictive and prognos-
tic indicators in patients with non-small-cell lung cancer treated with 
chemotherapy alone and in combination with erlotinib. J Clin Oncol 
2005;23:5900–5909.
 10. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome 
of patients with non-small cell lung cancer receiving front-line 
TABLE 2  Predictive Value of KRAS Mutational Status
Study Histology Type of Chemotherapy No. of Patientsa
KRAS  
Mut (%)
Response
KRAS  
Mut (%)
KRAS  
Wt (%) Predictive
Rodenhuis et al. 19978 Adenocarcinoma Mesna, ifosfamide, carboplatin, 
and etoposide
62 26 19 26 No
Eberhard et al. 20059 All Carbo/paclitaxel ± erlotinib 264 21 23 26 No
Kalikaki et al. 201010 All Several 133 23 25 27 No
aNumber of patients eligible for KRAS mutation analysis.
Wt, wild type; Mut, mutation; KRAS, Kirsten rat sarcoma viral oncogene homolog.
1195Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 9, September 2013  KRAS Mutations in Advanced Nonsquamous, NSCLC
chemotherapy according to EGFR and K-RAS mutation status. Lung 
Cancer 2010;69:110–115.
 11. Galleges Ruiz MI, Floor K, Steinberg SM, et al. Combined assessment 
of EGFR pathway-related molecular markers and prognosis of NSCLC 
patients. Br J Cancer 2009;100:145–152.
 12. Rossi G, Papotti M, Barbareschi M, Graziano P, Pelosi G. Morphology 
and a limited number of immunohistochemical markers may efficiently 
subtype non-small-cell lung cancer. J Clin Oncol 2009;27:e141–2; author 
reply e143.
 13. Kramer D, Thunnissen FB, Gallegos-Ruiz MI, et al. A fast, sensitive 
and accurate high resolution melting (HRM) technology-based assay to 
screen for common K-ras mutations. Cell Oncol 2009;31:161–167.
 14. Heideman DA, Lurkin I, Doeleman M, et al. KRAS and BRAF mutation 
analysis in routine molecular diagnostics: comparison of three testing 
methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J 
Mol Diagn 2012;14:247–255.
 15. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene 
in surgically resected non-small cell lung cancer patients. Oncogene 
1993;8:2407–2412.
 16. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi 
K. K-ras and p53 mutations are an independent unfavourable pro gnostic 
indicator in patients with non-small-cell lung cancer. Br J Cancer 
1997;75:1125–1130.
 17. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of 
p53 and K-ras mutations in primary resected non-small-cell lung can-
cer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative 
Oncology Group Prospective Randomized Trial of postoperative adjuvant 
therapy. J Clin Oncol 2001;19:448–457.
 18. Broermann P, Junker K, Brandt BH, et al. Trimodality treatment in Stage 
III nonsmall cell lung carcinoma: prognostic impact of K-ras mutations 
after neoadjuvant therapy. Cancer 2002;94:2055–2062.
 19. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in 
survival of patients with lung cancer: a systematic review of the literature 
with meta-analysis. Br J Cancer 2005;92:131–139.
 20. Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras 
mutations could affect drug sensitivity and tumour behaviour in non-
small-cell lung cancer. Ann Oncol 2011;22:235–237.
 21. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions 
on protein behavior: implications for signaling and clinical outcome. J 
Natl Cancer Inst 2012;104:228–239.m
 22. Kim E, Herbst R, Wistuba I, et al. The BATTLE Trial: personalizing ther-
apy for lung cancer cancer discovery 2011 June 2011;1:44–53.
